Royalty Pharma plc is a Humankind 100 company whose ranking is based on its Humankind Value, a proprietary metric that provides an estimate of the overall dollar amount a company creates for investors, consumers, employees, and society at large.
Royalty Pharma Plc buys biopharmaceutical royalties for promising R&D projects still in the clinical development stage. This helps fund the project while it is still being developed, which can help it reach the consumer market and improve health outcomes.
(All values are in US Dollars, where M=Million, B=Billion, T=Trillion.)
Healthcare is a central component of our measure of Humankind Value, as a large contribution to modern life expectancies has come from the last 150 years of medical innovation. Royalty Pharma Plc has earned a spot in our top 100 primarily due to Healthcare R&D ($57.0 B), Pharmaceuticals ($11.7 B), and Economic Value ($1.4 B). Positive value from Healthcare R&D and Pharmaceuticals includes the impact of an estimated 1,423,907.0 additional years lived by people worldwide. Its added economic value comes from offering to consumers goods and services that they value, paying employees for their labor in producing these goods and services, and providing value for shareholders. Downsides for this company are associated with Greenhouse Gases (-$157.5 M) and Air Pollution (-$35.8 M). Healthcare R&D, Pharmaceuticals, Economic Value, Greenhouse Gases, and Air Pollution are attached to this company as a result of its direct business activities.